Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The First Case of the Omicron Variant in the US is Confirmed …in a Fully-Vaccinated Person
https://www.washingtonpost.com/health/2021/12/01/omicron-in-the-us/
GTXO all the MORE reason we need others ways to combat covid and it’s variants. Imagine If more places installed Their revolutionary simple, seamless, and effective air purification technology that uses patented UV-C light air purification technology …. The vaccines might help mitigate symptoms but sadly most definitely aren’t stopping the spread of the virus … GTXO $$$
https://gtxcorp.com/gtx-signs-distribution-agreement-for-new-pathogen-control-technology/
Regarding the muscle rub heightened effectiveness … true story : My mom can be quite the skeptic… however … Mom had a sore shoulder… Dad said she should try the AELIA Medolife Rub. She applied some reluctantly. … Later Dad was looking for the AELIA muscle rub … Mom had it and was going to apply some again before bedtime. “It seemed to help” she said ;)
Translation of a skeptical mom words - it works great! She would have reverted to her other products if it hadn’t
I’m happy to report both of my parents are enjoying the relief from this product … I’m using the imunapen and have to say the taste is good, dare I say “yummy” … with all the variants of covid and entering “cold and flu season” I’m personally happy to be able to help out my immune system in any way I can)
Stay healthy everyone - wash hands and be conscious not to touch your face when out and about this busy bustling time of year
This Makes a Great holiday gift
https://aeliastore.com/
Great gift for aging parents as well as equally as great for young athletes too!!
I’ve heard first hand accounts of teens, middle age and elderly ALL very pleased with the effectiveness of the rub (bonus the scent is also pleasant which is a plus)
https://aeliastore.com/
Press Releases DECEMBER 02, 2021 8:00AM EST
https://ir.quantrx.com/news-events/press-releases/detail/97/medolife-rx-announces-results-of-comparative-study-of-its
“We have been looking forward to sharing these positive results with the world and see this as a steppingstone to solidifying Aelia’s position as a leader in topical pain relief products using CBD,” said Medolife CEO Dr. Arthur Mikaelian. “We have faith that in the future our proprietary polarization technology can become a standard in high-quality product formulations as we continue to expand on the science and capabilities of polarization.”
The First Case of the Omicron Variant in the US is Confirmed …in a Fully-Vaccinated Person
https://www.washingtonpost.com/health/2021/12/01/omicron-in-the-us/
“U.S. confirms nation's first case of omicron Covid variant in California”
https://www.google.com/amp/s/www.cnbc.com/amp/2021/12/01/us-confirms-nations-first-case-of-omicron-covid-variant-in-california.html
QNTA last cc the vaccine $cience was discussed, Dr Mikaelian had some very interesting slides at the 28:50 mark of the cc re vaccines
28:09 ish mark Is where the vaccine discussion gets very interesting…
Meeting Recording:
https://us06web.zoom.us/rec/share/h47AL256ftOOfGott6fn-lrzjME-COPJKrGsR3Bm4aGONV3ZmNmEEUPoQ9hwZug.uwvAtnFFv8J392-O
Access Passcode: ^9@23J$?
His relationship with the DR is good and a lasting ongoing one at that … read about the “Nagoya protocol” and then look at the following links … the meeting with the DR VP most recently is not an isolated meeting … the DR is VERY well informed aware and involved in seeing the scorpion ranch and subsequently MedolifeRx succeed ….
Here’s a couple links worth looking at
Nagoya Protocol… worth reading
This informative colorful pamphlet style link talks about it :
https://abs-sustainabledevelopment.net/wp-content/uploads/2019/05/Dominican-Republic-1.pdf
~~~~~~~~~~~~~~~
CEO Dr. Arthur Mikaelian received an achievement award from the “Defensa Civil Republica Dominicana” (The National District of Civil Defense) for his unconditional support of the cause of the agency and his work on Escozine® as a treatment for the SARS-CoV-2 (COVID-19) virus in the Dominican Republic (DR). The award was formally presented at a ceremony on Friday, May 14, where local leaders, such as the mayor, attended to recognize Dr. Mikaelian for his work.
https://finance.yahoo.com/news/medolife-rx-ceo-receives-achievement-120000358.html
Nagoya Protocol… worth reading
This informative colorful pamphlet style link talks about it :
https://abs-sustainabledevelopment.net/wp-content/uploads/2019/05/Dominican-Republic-1.pdf
~~~~~~~~~~~~~~~
CEO Dr. Arthur Mikaelian received an achievement award from the “Defensa Civil Republica Dominicana” (The National District of Civil Defense) for his unconditional support of the cause of the agency and his work on Escozine® as a treatment for the SARS-CoV-2 (COVID-19) virus in the Dominican Republic (DR). The award was formally presented at a ceremony on Friday, May 14, where local leaders, such as the mayor, attended to recognize Dr. Mikaelian for his work.
https://finance.yahoo.com/news/medolife-rx-ceo-receives-achievement-120000358.html
Well yes the Fda is definitely an important thing… it’s worth noting that other countries can and will sell things that are not FDA approved the entire population of the world is much greater than the population of the US we tend to always believe the gold standard is the FDA and the only thing that will let things go forward it’s simply not true it is most definitely good and they are striving for it and I believe will achieve FDA approval in time in the meantime though getting the blessings of the Dominican republic an approval there And their help and willingness to promote their product which I’ll listen to the recording again encourage others to as well it is talked about in there that they are having a meeting at some point with other nations from Latin America
PzKz this is great
[{“Picture Proof CEO met Dominican Republic Vise President Raquel Peña.
insert-text-here
Click one of the photos from the gallery and the text reads...(Google translated from Spanish)
"Meeting Dr. Arthur Mikaelian & Dra. Ana Rodríguez
The vice president Raquel Peña received in her office she received Drs. Arthur Mikaelian & Ana Rodríguez. Santo Domingo Dominican Republic. October 13, 2021. Vp / Jhon Escalante
Uploaded October 13, 2021
Photo: Jhon Escalante"
I think this is an official website for the Vise President. It links to all her social media, photo galleries, and news relating to her.
Oct. 13 is the same date mentioned in QNTA's Oct. 14 PR
"Medolife Rx Announces that the Government of the Dominican Republic is Willing to Include Escozine into its COVID-19 Treatment Regimen"
Here's a quote from that PR...
"In an in-person meeting, which took place at government facility in Santo Domingo on 10/13/21, the Company presented findings from its study on the effects of Escozine on 450 patients who had tested positive for COVID-19. After reviewing the findings, the Vice President of the DR, who has been tasked with overseeing the COVID-19 response by the government of the DR, expressed appreciation for the support of the country by Medolife and her belief in the importance of Escozine for the country. Further, she shared that she would be supportive of immediately forming a government committee in the DR that would expedite the processing of the product, allowing for rapid distribution of Escozine® throughout the country. A committee could be organized as quickly as within a week. Beyond the distribution of Escozine® throughout the DR, the Vice President also expressed a strong desire to solidify an agreement to introduce the benefits and effectiveness of Escozine® as a COVID-19 therapy to other countries. Finally, the VP shared that she will look to make plans to visit the Company’s first-of-its-kind scorpion reservation and manufacturing facility."
I'm no expert, but this looks legit to me. Can anyone who thinks this is a scam explain away this photo gallery? “}]
at 28:50 mark of the cc re vaccines
Is where the vaccine discussion gets very interesting
Meeting Recording:
https://us06web.zoom.us/rec/share/h47AL256ftOOfGott6fn-lrzjME-COPJKrGsR3Bm4aGONV3ZmNmEEUPoQ9hwZug.uwvAtnFFv8J392-O
Access Passcode: ^9@23J$?
Great video Scorpions $cience
far reaching applications…
At the 19:05 time mark
Ibuprofen is discussed
Access passcode and CC LINK
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Start Time: Nov 23, 2021 01:44 PM
Meeting Recording:
https://us06web.zoom.us/rec/share/h47AL256ftOOfGott6fn-lrzjME-COPJKrGsR3Bm4aGONV3ZmNmEEUPoQ9hwZug.uwvAtnFFv8J392-O
Access Passcode: ^9@23J$?
Access passcode and CC LINK
Topic: Medolife Rx (Quanta, Inc. OTC: QNTA) Investor Conference Call
Start Time: Nov 23, 2021 01:44 PM
Meeting Recording:
https://us06web.zoom.us/rec/share/h47AL256ftOOfGott6fn-lrzjME-COPJKrGsR3Bm4aGONV3ZmNmEEUPoQ9hwZug.uwvAtnFFv8J392-O
Access Passcode: ^9@23J$?
I was unable to hear most of the CC .. so now I am waiting for the recording of the CC, I was in an airport while trying to listen in addition to terrible reception I was dealing with flights changing and subsequently missed most of what was said. I’ll post the recorded link as soon as I obtain it.
Pre-IND / NDA STRATEGY
Escozine®/ Covid-19: Data on Escozine® has been filed under pre-IND with US FDA as a potential COVID1-19. Clinical studies showing efficacy and safety of product
Escozine® GNP-1/ Pancreatic Cancer (Orphan Drug):
As a critical medicine for the Covid-19 Pandemic, we anticipate the approval of the product, in a shorter time period. Given that Scorpion Peptide is the main ingredient for Escozine/ Covid-19 and Escozine GNP-1, we strategize that the approval of the Escozine/Covid-19 drug can facilitate the fast tracking to the second phase of Escozine GNP-1/Pancreatic Cancer drug study.
https://medoliferx.com/clinical-strategy/
Cyber Monday shopping :)
I’m waiting on the recording … I want to relisten to the new science about the “not” mRNA science that Dr Makaelian was talking about … it was incredibly interesting. With variants ever evolving there has to be a better solution to never ending boosters … the escozine is one part … it sounded like the science he was discussing could very well be a much better approach than the current mRNA type vaccine being used … I know it took a few days last time for the recording of the cc to post. If any one gets the link please share :) I’ll post as soon as I obtain it if not posted already
Immunapen the drops taste good :)
I’m not sure what I expected but I didn’t expect to think this tastes yummy lol but that’s exactly what I thought ;)
https://medoliferx.com/shop/drops/escozine-immunapen-original-drops/
I have had year round environmental and seasonal allergies for years … I’m anxious to see if in addition to helping boost my immune system if the imunapen will have any positive effect on my allergies.. I’ll keep everyone posted. But in the mean time - my order arrived promptly and the taste is good. Both are good things
… I have not personally used the muscle rub yet but I know people who’ve been really happy with it.
Hope everyone’s thanksgiving was good. Safe travels to everyone.
Powerbattles,
… hopefully not …
I think In part they had a cc because of all the pressure from investors to answer questions … they hoped I’m sure reiterating the DR escozine deal would prove the shed optimism… with the new variant now out I’m hopeful that escozine can get fast tracked as one of the significant things said has been that escozine mitigated side affects of the vaccine … this alone is huge
I hope everyone had a great thanksgiving
.. wishing safe travels to all who are on the roads and in airports
Scientists in South Africa on Thursday identified a concerning new coronavirus variant with mutations that one scientist said marked a “big jump in evolution,” prompting several countries to quickly limit travel from the region.
Within hours, Britain, Israel and Singapore had restricted travel from South Africa and some neighboring countries, citing the threat of the new variant.
https://www.google.com/amp/s/www.nytimes.com/2021/11/25/world/variant-south-africa-covid.amp.html
~~~~~~
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/medolife-rx-announces-government-dominican-123000490.html
Vice President of the DR, who has been tasked with overseeing the COVID-19 response by the government of the DR, expressed appreciation for the support of the country by Medolife and her belief in the importance of Escozine for the country.
I was only able to listen in intermediates as I was in an airport … I’m waiting to hear the full uninterrupted recording as well. When the recording becomes available you should be able to find it here https://ir.quantrx.com/news-events/ir-calendar/detail/7480/medolife-rx-third-quarter-2021-conference-call
In the mean time A new covid variant has apparently been labeled … qnta has the science to help … once they get the testing completed, as this is where a huge portion of funding is going … the DR is in a partnership with qnta and has interest in seeing MedolifeRx do well. Keep in mind other countries outside the us, like India for example, welcome alternative methods to combat covid - like ivermectin and hydroxychloriquine for example both are readily available over the counter and widely used … also very much worth noting the escozine showed to reduce / quell side effects when taking the escozine .. that alone is huge! Never mind it is shown to help those who have it
That’s I see it too
Weirder things have happened….
It’s always good to have a dream
… as sometimes they come true ;~}
Happy thanksgiving everyone
Safe travels to all who are driving / flying
Happy thanksgiving everyone
“I hope the CC can give some ease to our investors.”
Quoted from an email I received back from qnta
Let’s wait and hear the cc.
I’ll be traveling so will have to hear the recording of it when recording gets posted
Happy thanksgiving and safe travels to everyone
The “whistle blower” could very well be an impatient iHub investor as well .. this is a long play … the very fact they are having a cc today is actually very encouraging… they are literally listening to the investors and using this format to publicly address many topics … they have great science .. and that’s what brought me here … the mis steps they’ve made (like the rs debacle this summer) are the inexperience of the company with the otc … they listened and altered course and were forthcoming about it. … I’d say it’s 100% worth hearing what they have to say today
I’m holding and long still
I think while before we all get too carried away with theory… we should listen to the cc and get clarity - here’s the link for any one not yet signed up :
Link for Cc for investors Tuesday, November 23rd.
*** CC registration link ***
To register for this call, please use the below web link: https://us06web.zoom.us/webinar/register/WN_FDQO-lDCTQ2TrwtTgdAdTQ
:) agreed
Link for Cc for investors Tuesday, November 23rd.
*** CC registration link ***
To register for this call, please use the below web link: https://us06web.zoom.us/webinar/register/WN_FDQO-lDCTQ2TrwtTgdAdTQ
SEC Filing Alert link at the bottom
10-Q: Quarterly report pursuant to Section 13 or 15(d)
If you have any questions, or would like to contact Investor Relations, please reply to this email.
Quanta, Inc.
3606 W Magnolia Blvd, Burbank, CA 91505 United States of America
https://quantrx.com
https://d1io3yog0oux5.cloudfront.net/sec/0001493152-21-029568/0001493152-21-029568.pdf
question submit (due noon today) Reminder - CC is tomorrow:
Cc for investors Tuesday, November 23rd.
*** full news release pasted below CC registration link ***
To register for this call, please use the below web link: https://us06web.zoom.us/webinar/register/WN_FDQO-lDCTQ2TrwtTgdAdTQ
If you have questions, please send an email to medolife@cmwmedia.com with ‘QNTA Question’ in the subject line by NOON Eastern Daylight Time on Monday, November 22. Management will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available in the following days.
********
Full link below :
https://ir.quantrx.com/news-events/press-releases/detail/96/medolife-rx-schedules-conference-call-with-investment
BURBANK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has scheduled a conference call with investors for Tuesday, November 23rd.
Conference Call Topics:
Bi-annual visit and filing with Ministry of Environment;
Tony Hawk ad campaign;
257% increase in efficacy of Ibuprofen using proprietary polarization technique from internal study;
Update on comparative study on CBD muscle rub, which showed a significant efficacy increase caused by polarization technology;
Update on progress with the government of the Dominican Republic;
Update on FINRA on the name and symbol change;
Update on the AELIA comparative study;
Update on Mexico distribution;
Update on social media sales programs;
Update on big box retailer conversations;
New business verticals, such as polarized ribosomes.
“The third quarter was uniquely important for Medolife as we continued to focus both on our relationship with the government of the Dominican Republic and monetizing the Escozine product line, as well as on increasing sales of our consumer Aelia product lines,” said Medolife CEO Dr. Arthur Mikaelian. “As a full-scale life sciences company, navigating the regulatory frameworks of both the pharmaceutical and nutraceutical industries is challenging and time consuming. That said, I could not be prouder of how far we have come in such a short time. We are on the precipice of a deal with the DR that would dramatically expedite the growth of our Escozine product line and open up new channels of distribution, enabling us to bring these medically beneficial products to patients globally. Additionally, our Aelia product line continues to see a great response from consumers, and we remain confident on our position with the FDA in our PIND filing. All in all, we are extremely confident about the future of Medolife.”
“We have always strived for transparency and open communication with our current and potential investors. That is why we will be hosting a conference call next week. We plan to discuss the third quarter, current updates on the various aspects of the company, and address questions as much as possible. We encourage our shareholders to attend, and we look forward to the opportunity,” added Mikaelian.
Dr. Mikaelian and Quanta, Inc. acting-CFO Clemente Pascarella will hold a conference call with the investment community on Tuesday, November 23, at 5 p.m. Eastern Standard Time. They will present on the Company’s milestones achieved in the quarter, as well as the future positioning of the Company. Additionally, the two will take questions from the investment community at the end of the call.
To register for this call, please use the below web link: https://us06web.zoom.us/webinar/register/WN_FDQO-lDCTQ2TrwtTgdAdTQ
If you have questions, please send an email to medolife@cmwmedia.com with ‘QNTA Question’ in the subject line by NOON Eastern Daylight Time on Monday, November 22. Management will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available in the following days.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine® ®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® ® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary AELIA, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. AELIA products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
ir@medoliferx.com
Cc for investors Tuesday, November 23rd.
*** full news release pasted below CC registration link ***
To register for this call, please use the below web link: https://us06web.zoom.us/webinar/register/WN_FDQO-lDCTQ2TrwtTgdAdTQ
If you have questions, please send an email to medolife@cmwmedia.com with ‘QNTA Question’ in the subject line by NOON Eastern Daylight Time on Monday, November 22. Management will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available in the following days.
********
Full link below :
https://ir.quantrx.com/news-events/press-releases/detail/96/medolife-rx-schedules-conference-call-with-investment
BURBANK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that it has scheduled a conference call with investors for Tuesday, November 23rd.
Conference Call Topics:
Bi-annual visit and filing with Ministry of Environment;
Tony Hawk ad campaign;
257% increase in efficacy of Ibuprofen using proprietary polarization technique from internal study;
Update on comparative study on CBD muscle rub, which showed a significant efficacy increase caused by polarization technology;
Update on progress with the government of the Dominican Republic;
Update on FINRA on the name and symbol change;
Update on the AELIA comparative study;
Update on Mexico distribution;
Update on social media sales programs;
Update on big box retailer conversations;
New business verticals, such as polarized ribosomes.
“The third quarter was uniquely important for Medolife as we continued to focus both on our relationship with the government of the Dominican Republic and monetizing the Escozine product line, as well as on increasing sales of our consumer Aelia product lines,” said Medolife CEO Dr. Arthur Mikaelian. “As a full-scale life sciences company, navigating the regulatory frameworks of both the pharmaceutical and nutraceutical industries is challenging and time consuming. That said, I could not be prouder of how far we have come in such a short time. We are on the precipice of a deal with the DR that would dramatically expedite the growth of our Escozine product line and open up new channels of distribution, enabling us to bring these medically beneficial products to patients globally. Additionally, our Aelia product line continues to see a great response from consumers, and we remain confident on our position with the FDA in our PIND filing. All in all, we are extremely confident about the future of Medolife.”
“We have always strived for transparency and open communication with our current and potential investors. That is why we will be hosting a conference call next week. We plan to discuss the third quarter, current updates on the various aspects of the company, and address questions as much as possible. We encourage our shareholders to attend, and we look forward to the opportunity,” added Mikaelian.
Dr. Mikaelian and Quanta, Inc. acting-CFO Clemente Pascarella will hold a conference call with the investment community on Tuesday, November 23, at 5 p.m. Eastern Standard Time. They will present on the Company’s milestones achieved in the quarter, as well as the future positioning of the Company. Additionally, the two will take questions from the investment community at the end of the call.
To register for this call, please use the below web link: https://us06web.zoom.us/webinar/register/WN_FDQO-lDCTQ2TrwtTgdAdTQ
If you have questions, please send an email to medolife@cmwmedia.com with ‘QNTA Question’ in the subject line by NOON Eastern Daylight Time on Monday, November 22. Management will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available in the following days.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine® ®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® ® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary AELIA, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. AELIA products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
ir@medoliferx.com
Great points made PennyWorld
I agree wholeheartedly with all you said. I’m holding long here as I’ve invested in the science… the company is small but has great data to back up their science, products, patents etc … also the scorpion ranch expansion & positive support of the Dominican Republic is great and noteworthy.
GLTA
In the meantime their products are great!! And available online … to get folks interested in the stock / company one great way to do that is to purchase a product as a gift for some one who could greatly benefit… the gift receiver is highly likely to become a customer ;)
Suddenly, more QNTA bidders (300k) than askers (10k) — green up 5.8%
Should read “News” not need
Good morning all .. I’m still working on my first coffee of the day. Happy Wednesday and GLTA
QNTA MedolifeRx AELIA escozine
https://aeliastore.com/
https://medoliferx.com/
True … but, they can’t hardly push need they have not received YET … the test results take time … that’s the big news we should all be optimistic and looking forward to hearing … hopefully we hear soon as absolutely some energizing news would be (will be) great to hear.
QNTA **** Holidays are fast approaching.. all who I know who have purchased and tried the products really like them. Here’s the links *** these items make great gifts that the recipient is very likely to subsequently become a return customer;)
Imunapen
https://medoliferx.com/
Muscle Rub
https://aeliastore.com/
You aren’t confused.. you are correct in your thinking … pre AELIA though there had been a brief interim name for products but there was a name conflict of sorts…
Things are all coming together … the slow down was in large part because of the the fda adding in the newly required dna test, and then the packaging delay, couple that all with various events (specifically the nfl one) having to be adjusted due to California covid attendance regulations etc etc … given the head winds they are operating under they are still moving forward … at least, IMO that is, things are going forward … just slowly … it’ll all catapult once the big hurdles get cleared
… In the mean time … waiting is like watching paint dry …
It’ll take some searching, as I don’t recall when exactly it was explained, however the name change occured when the name choice chosen prior to Aelia for products was found to already be in use globally? Or some such thing … it’s on one of Cc calls from this summer … they explained the why / how etc … and Aelia was chosen as a nod to Makaelian name …
As far as looking at it another way, the word has a nice meaning as
Aelia means “sun”, “sunlight” and “sunshine” (from ancient Greek “helios/?????”).
DR Scorpion ranch {“Director of Biodiversity of the MOE, Gabriel Valdez, and his team visited the facility and shared an overall positive assessment of the facility.”}
Full article and link below:
Medolife Rx Completes Bi-Annual Visit From Ministry of Environment to Scorpion Reservation, Receives Positive Feedback and Re-Affirmation of Joint Venture
Quanta, Inc.
September 15, 2021, 8:30 am
BURBANK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTCQB: QNTA), announced today that the Company received positive feedback from its bi-annual visit by the Ministry of Environment (MOE) of the Dominican Republic (DR) to its scorpion reservation in the local Neyba province. The formal visit resulted as part of the joint venture partnership between Medolife and the MOE by the surveying commission, where the Company was able to meet certain contract points of the agreement.
The Company has been engaged with the MOE of the DR in a joint venture on the development of a scorpion reservation and investigation on endemic wildlife in the Neyba province since 2008. The facility build-out has been taking place since that time and, per the recently renewed agreement in place with the MOE, the facility was to be visited by the regulatory body bi-annually to assess construction progress, animal safety, and overall compliance with the labor and safety standards of the MOE. The visit took place on September 11, 2021, where The Director of Biodiversity of the MOE, Gabriel Valdez, and his team visited the facility and shared an overall positive assessment of the facility. This assessment included the acknowledgement of three key areas: the high level of training for workers at the reservation, the conclusion that the scorpions being raised in the facility are being properly taken care of, and overall positive socio-economic and health impact the facility is having on the region. This assessment led to the satisfaction of the purpose of the visit and the renewal of the ongoing relationship between the MOE and Medolife.
“Our relationship and partnership with the MOE and government of the DR is vital not only to our ethos of doing good for our community, but to the greater success of Medolife,” said Medolife CEO Dr. Arthur Mikaelian. “We were almost certain that the visit would take place without issue; however, the positivity of the response we received surpassed our own expectations. Director Valdez was so kind in his words and assessment of our progress, and how we are positively impacting the community. We took every step to ensure not only that the scorpions are taken care of, but the people we employ found the job both safe and rewarding. This was observed by the visiting commission, and we couldn’t be more pleased to continue on with our relationship with the MOE.”
The scorpion reservation serves as the Company’s main source of peptide production that is used in most of its pharmaceutical and nutraceutical products. Scorpion venom is one of the most expensive liquids in the world and this facility represents one of the largest reservations of its kind globally. Through it, Medolife owns its supply of these crucial peptides without the reliance and variability of third-party sources.
The Company has been working to build out the facility and the demand for Medolife products continues to grow. The peptides produced from the facility go through a polarization process proprietary to Medolife that increases their potency by up to five times. Those peptides are then used in the Company’s nutraceutical product line, Immunapen™, which features four distinct formulations that assist consumers with everyday issues such as stress relief and energy aid, as well as its lead drug candidate Escozine®, which is currently undergoing clinical trials under US Food and Drug Administration (FDA) review under a pre-Investigational New Drug Application (Pre-IND) as a treatment for the SARS-CoV-2 virus that spawned the ongoing COVID-19 pandemic
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness and nutraceutical products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology which applies advances in quantum biology to increase the potency of active ingredients. Currently, QuantRx supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/medolife-rx-completes-bi-annual-123000204.html